[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368592-105":59,"doc-detail-368592-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","cd84-as-a-prognostic-biomarker-and-therapeutic-target-in-breast-cancer-interconnections-with-pdl1-cd74-and-immune-tolerance-mechanisms","CD84 as a Prognostic Biomarker and Therapeutic Target in Breast Cancer - Interconnections With PDL1, CD74, and Immune Tolerance Mechanisms","","CD84, a SLAM-family immune cell-surface immunoreceptor, is investigated as a prognostic biomarker and therapeutic target in breast cancer. CD84 mRNA expression and its relationship with clinicopathological parameters are assessed in a well-characterised cohort. Quantitative real-time PCR measures CD84 and related immune-tolerance molecules, including PDL1 and CD74. Higher CD84 predicts poorer overall survival independent of established prognostic factors.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cd84-as-a-prognostic-biomarker-and-therapeutic-target-in-breast-cancer-interconnections-with-pdl1-cd74-and-immune-tolerance-mechanisms/368592/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cd84-as-a-prognostic-biomarker-and-therapeutic-target-in-breast-cancer-interconnections-with-pdl1-cd74-and-immune-tolerance-mechanisms/368592.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main focus regarding CD84 in breast cancer?","Question",{"text":112,"@type":113},"The study evaluates whether CD84 expression can function as a prognostic biomarker and therapeutic target in breast cancer, and how it relates to immune tolerance mechanisms.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were CD84 and related immune markers measured?",{"text":117,"@type":113},"CD84 and associated molecules, including PDL1 and CD74, were quantified using quantitative real-time PCR (qPCR) to assess mRNA expression levels.",{"name":119,"@type":110,"acceptedAnswer":120},"What prognostic impact did CD84 expression have?",{"text":121,"@type":113},"Elevated CD84 expression predicted poorer overall survival, remaining significant even after accounting for conventional prognostic factors such as the Nottingham Prognostic Index (NPI).",{"name":123,"@type":110,"acceptedAnswer":124},"Why is CD84 considered relevant to immune tolerance and treatment resistance?",{"text":125,"@type":113},"CD84 showed significant correlations with immunosuppressive molecules such as PDL1 and CD74, supporting a role in fostering immune tolerance and facilitating immune evasion in the tumour microenvironment.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},368592,1790785122,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","doi: 10.21873/cgp.20521  \nCD84 as a Prognostic Biomarker and Therapeutic Target in Breast Cancer: Interconnections With PDL1, CD74, and Immune Tolerance Mechanisms  \nUMAR WAZIR1, AMBER X. LI2, CAROLYN CAI WANG2, HENSON HAN GAO2, TRACEY A. MARTIN2, WEN G. JIANG2 and KEFAH MOKBEL1,2  \n1The London Breast Institute, Princess Grace Hospital, London, U. K.;  \n2 Metastasis Research Group, University of Wales College of Medicine, Cardiff, U. K.  \nAbstract  \nBackground/Aim: Cluster of differentiation 84 (CD84), a member of the signalling lymphocytic activating molecule (SLAM) family, has emerged as a potential prognostic biomarker and therapeutic target in breast cancer. This study explored CD84 expression and its correlation with clinicopathological features in a well‑characterised cohort. Materials and Methods: Using quantitative real‑time PCR, mRNA expression levels of CD84 and related molecules, including PDL1, CD74, and other immune tolerance markers, were analysed.  \nResults: The findings reveal that elevated CD84 expression predicts poor overall survival, independent of conventional prognostic factors such as the Nottingham Prognostic Index (NPI) . Notably, a combined signature of CD84, CD48, VAV1, and CTNNB1 demonstrated stronger prognostic power than individual markers. CD84 exhibited significant correlations with immunosuppressive molecules, including PDL1 and CD74, underscoring its role in fostering immune tolerance within the tumour microenvironment.  \nConclusion: CD84 may mediate an immunosuppressive phenotype, facilitating immune evasion in breast cancer. This highlights its potential as a therapeutic target, particularly in triple‑negative breast cancer, to overcome immune resistance and enhance treatment efficacy.  \nKeywords: CD84, CD74, VAV1, CTNNB1, CD48, PD‑L1, breast cancer, immune tolerance, checkpoint inhibitors, TNBC, immunotherapy.  \nIntroduction  \nCluster of differentiation 84, also known as signalling lymphocytic activating molecule 5 (CD84/SLAMF5) has  \nbeen known to be an immune cell marker and a member of the signalling lymphocytic activating molecule (SLAM) family of cell‑surface immunoreceptors (1) . Its role in immunity and autoimmune conditions has been studied  \n✉  \nProf. Kefah Mokbel, The London Breast Institute, The Princess Grace Hospital, 42‑52 Nottingham Place, London W1U 5NY,  \nU. K. E‑[mail: Kefah.Mokbel@hcahealthcare.co.uk](mail: Kefah.Mokbel@hcahealthcare.co.uk)  \nReceived April 20, 2025 | Revised May 5, 2025 | Accepted May 7, 2025  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n©2025 The Author(s) . Anticancer Research is published by the International Institute of Anticancer Research.  \nextensively (2) . CD84, along with other members of the SLAM family, plays a role in multiple myeloma (3) and other blood cancers (4).  \nMore recently, evidence suggests a role for CD84 in breast cancer. Specifically, it has been proposed as a therapeutic target for breaking immune tolerance in triple‑negative breast cancer (TNBC) (5) . This adds to earlier evidence of the role of related molecules in breast cancer tolerance to chemotherapy (6).  \nIn this study, we examine the correlations between CD84 and clinicopathological characteristics in breast cancer within a well‑documented cohort, as well as the roles of other known members of CD84‑related pathways.  \nMaterials and Methods  \nSamples. Following ethical approval from the Bro Taf Health Authority (ethics approval numbers 01/4303 and 01/4046) and after obtaining informed consent, tissue samples were collected. Immediately after surgical removal, a sample was taken from the tumour itself, and a second sample was collected from adjacent non‑cancerous tissue within 2 cm of the tumour. This adjacent tissue served as a control for comparison with the cancerous tissue and did not interfere with the asses","cbCaimmbSaC6CF71","https://ap.wps.com/l/cbCaimmbSaC6CF71","pdf",582765,"English","# Abstract\n# Introduction\n# Materials and Methods\n## Samples\n## Tissue processing, RNA extraction and cDNA synthesis\n## Quantitative analysis","[{\"question\":\"What is the study’s main focus regarding CD84 in breast cancer?\",\"answer\":\"The study evaluates whether CD84 expression can function as a prognostic biomarker and therapeutic target in breast cancer, and how it relates to immune tolerance mechanisms.\"},{\"question\":\"How were CD84 and related immune markers measured?\",\"answer\":\"CD84 and associated molecules, including PDL1 and CD74, were quantified using quantitative real-time PCR (qPCR) to assess mRNA expression levels.\"},{\"question\":\"What prognostic impact did CD84 expression have?\",\"answer\":\"Elevated CD84 expression predicted poorer overall survival, remaining significant even after accounting for conventional prognostic factors such as the Nottingham Prognostic Index (NPI).\"},{\"question\":\"Why is CD84 considered relevant to immune tolerance and treatment resistance?\",\"answer\":\"CD84 showed significant correlations with immunosuppressive molecules such as PDL1 and CD74, supporting a role in fostering immune tolerance and facilitating immune evasion in the tumour microenvironment.\"}]","CD84 as a Prognostic Biomarker and Therapeutic Target in Breast Cancer - Interconnections With PDL1, CD74, and Immune Tolerance Mechanisms | PDF",1790177637,18,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b090873304848ea05c9b8ba6f7ebce0c.webp",983,1301,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1b9c9d1b76d7e4581c2e3dab53908c1.webp",982,1299,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4de6545cae8d19b534385ceef0b0ab93.webp",981,1298,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb605a8efb1c41c2e92398648001d81e.webp",980,1297]